委员会认证的重症监护培训设施对严重呼吸衰竭辅助治疗选择及预后的影响:一项全国性队列研究
该回顾性队列研究利用日本2016至2019年全国住院患者数据库,纳入需机械通气超过4天的非手术严重呼吸衰竭患者共66,905例,其中30,588例在要求至少配备一名重症监护医师的委员会认证设施治疗,36,317例在非认证设施治疗。认证设施更多使用丙泊酚(35% vs 18%)、右美托咪定(37% vs 19%)、芬太尼(50% vs 20%)等辅助治疗,较少使用多巴胺(9.0% vs 15%)、西维来司他(4.1% vs 7.0%)和大剂量甲泼尼龙(13% vs 15%)。经1:1倾向评分匹配后,认证组院内死亡率低于非认证组(31% vs 38%;OR 0.75;95%CI 0.72-0.77;P<0.001)。亚组分析显示老年患者、机械通气首日需血管升压药者及在重症监护病房治疗者获益更大。作者认为因多种因素可能影响结局,因果关系仍不确定,需进一步研究如何通过认证重症监护培训设施最佳地改善危重症医疗体系中的患者结局。
要点
- 倾向评分匹配后,委员会认证设施组院内死亡率低于非认证组(31% vs 38%;OR 0.75;95%CI 0.72-0.77;P<0.001)。
- 认证设施更多使用丙泊酚(35% vs 18%)、右美托咪定(37% vs 19%)、芬太尼(50% vs 20%)、罗库溴铵(8.5% vs 2.6%)、去甲肾上腺素(35% vs 19%)和早期肠内营养(29% vs 14%)。
- 认证设施更多使用肾脏替代治疗(15% vs 6.7%)、体外膜氧合(1.6% vs 0.3%)和重症监护病房收治(74% vs 30%)。
- 非认证设施更多使用多巴胺(15% vs 9.0%)、西维来司他(7.0% vs 4.1%)和大剂量甲泼尼龙(15% vs 13%)。
- 亚组分析显示认证设施在老年患者、机械通气首日需血管升压药者及在重症监护病房治疗者中获益更大。
适用人群与场景
- 日本2016至2019年全国住院患者数据库中,非手术的严重呼吸衰竭且需要机械通气超过4天的患者。
- 共纳入66,905例,其中30,588例在委员会认证重症监护培训设施治疗,36,317例在非认证设施治疗。
处置流程与药物剂量
- 委员会认证重症监护培训设施要求至少配备一名重症监护医师。
- 在认证设施中,丙泊酚使用率为35%、右美托咪定37%、芬太尼50%、罗库溴铵8.5%、维库溴铵1.9%、去甲肾上腺素35%、精氨酸加压素8.1%、肾上腺素2.3%、多巴酚丁胺8.7%、磷酸二酯酶抑制剂1.0%、早期肠内营养29%、早期康复34%、肾脏替代治疗15%、体外膜氧合1.6%、重症监护病房收治74%。
- 在非认证设施中,丙泊酚使用率为18%、右美托咪定19%、芬太尼20%、罗库溴铵2.6%、维库溴铵0.6%、去甲肾上腺素19%、精氨酸加压素2.0%、肾上腺素1.0%、多巴酚丁胺4.8%、磷酸二酯酶抑制剂0.3%、早期肠内营养14%、早期康复30%、肾脏替代治疗6.7%、体外膜氧合0.3%、重症监护病房收治30%。
- 在非认证设施中,多巴胺使用率为15%、西维来司他7.0%、大剂量甲泼尼龙15%;在认证设施中分别为9.0%、4.1%、13%。
研究设计与关键结果
- 研究类型为回顾性队列研究,使用日本2016至2019年全国住院患者数据库,纳入非手术严重呼吸衰竭需机械通气超过4天的患者,共66,905例。
- 比较委员会认证重症监护培训设施(要求至少一名重症监护医师)与非认证设施的治疗和院内死亡率,采用倾向评分匹配。
- 认证设施与非认证设施在以下治疗上存在差异:丙泊酚(35% vs 18%)、右美托咪定(37% vs 19%)、芬太尼(50% vs 20%)、罗库溴铵(8.5% vs 2.6%)、维库溴铵(1.9% vs 0.6%)、去甲肾上腺素(35% vs 19%)、精氨酸加压素(8.1% vs 2.0%)、肾上腺素(2.3% vs 1.0%)、多巴酚丁胺(8.7% vs 4.8%)、磷酸二酯酶抑制剂(1.0% vs 0.3%)、早期肠内营养(29% vs 14%)、早期康复(34% vs 30%)、肾脏替代治疗(15% vs 6.7%)、体外膜氧合(1.6% vs 0.3%)、重症监护病房收治(74% vs 30%)、多巴胺(9.0% vs 15%)、西维来司他(4.1% vs 7.0%)、大剂量甲泼尼龙(13% vs 15%)。
- 经1:1倾向评分匹配后,认证组院内死亡率低于非认证组(31% vs 38%;比值比0.75;95%置信区间0.72-0.77;P<0.001)。
- 亚组分析显示认证组在老年患者、机械通气首日需血管升压药者及在重症监护病房治疗者中获益更大。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 作者指出因多种因素可能影响结局,因果关系仍不确定;需要进一步研究以确定如何通过认证重症监护培训设施最佳地改善危重症医疗体系中的患者结局。
对床旁实践的改变
- 该研究提示,在需机械通气超过4天的非手术严重呼吸衰竭患者中,委员会认证重症监护培训设施与较低的院内死亡率相关(31% vs 38%;OR 0.75;95%CI 0.72-0.77;P<0.001)。
- 作者认为因多种因素可能影响结局,因果关系仍不确定,需进一步研究如何通过认证重症监护培训设施最佳地改善危重症医疗体系中的患者结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with severe respiratory failure have high mortality and need various interventions. However, the impact of intensivists on treatment choices, patient outcomes, and optimal intensivist staffing patterns is unknown. In this study, we aimed to evaluate treatments and clinical outcomes for patients at board-certified intensive care training facilities compared with those at non-certified facilities.
METHODS: This retrospective cohort study used Japan's nationwide in-patient database from 2016 to 2019 and included patients with non-operative severe respiratory failure who required mechanical ventilation for over 4 days. Treatments and in-hospital mortality were compared between board-certified intensive care facilities requiring at least one intensivist and non-certified facilities using propensity score matching.
RESULTS: Of the 66,905 patients in this study, 30,588 were treated at board-certified facilities, and 36,317 were not. The following differed between board-certified and non-certified facilities: propofol (35% vs. 18%), dexmedetomidine (37% vs. 19%), fentanyl (50% vs. 20%), rocuronium (8.5% vs. 2.6%), vecuronium (1.9% vs. 0.6%), noradrenaline (35% vs. 19%), arginine vasopressin (8.1% vs. 2.0%), adrenaline (2.3% vs. 1.0%), dobutamine (8.7% vs. 4.8%), phosphodiesterase inhibitors (1.0% vs. 0.3%), early enteral nutrition (29% vs. 14%), early rehabilitation (34% vs. 30%), renal replace therapy (15% vs. 6.7%), extracorporeal membrane oxygenation (1.6% vs. 0.3%), critical care unit admission (74% vs. 30%), dopamine (9.0% vs. 15%), sivelestat (4.1% vs. 7.0%), and high-dose methylprednisolone (13% vs. 15%). After 1:1 propensity score matching, the board-certified group had lower in-hospital mortality than the non-certified group (31% vs. 38%; odds ratio, 0.75; 95% confidence interval, 0.72-0.77; P < 0.001). Subgroup analyses showed greater benefits in the board-certified group for older patients, those who required vasopressors on the first day of mechanical ventilation, and those treated in critical care units.
CONCLUSIONS: Board-certified intensive care training facilities implemented several different adjunctive treatments for severe respiratory failure compared to non-board-certified facilities, and board-certified facilities were associated with lower in-hospital mortality. Because various factors may contribute to the outcome, the causal relationship remains uncertain. Further research is warranted to determine how best to strengthen patient outcomes in the critical care system through the certification of intensive care training facilities.
参考来源
- Yoshida T, Shimizu S, Fushimi K, et al. Impact of board-certified intensive care training facilities on choice of adjunctive therapies and prognosis of severe respiratory failure: a nationwide cohort study. J Intensive Care. 2024. PMID: 39696527. doi:10.1186/s40560-024-00766-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。